Novel PET agent effectively detects multiple cancers, identifies patients for targeted therapies

Novel PET Agent Effectively Detects Multiple Cancers, Identifies Patients for Targeted Therapies
Graphical abstract. Credit: Journal of Nuclear Medicine (2022). DOI: 10.2967/jnumed.121.263693

A new molecular imaging radiotracer can precisely diagnose a variety of cancers, providing a roadmap to identify patients who may benefit from targeted radionuclide therapies. In the largest medical study of its kind, researchers found that 68Ga-PentixaFor demonstrated high image contrast in hematologic malignancies, small cell lung cancer, and adrenocortical neoplasms.

This research was published in the November issue of the Journal of Nuclear Medicine.

The 68Ga-PentixaFor is used to detect the C-X-C motif chemokine receptor 4 (CXCR4). Chemokine receptor expression is a predictor of poor prognosis in , as it promotes the growth of malignant cells and inhibits anti-tumor response.

"Knowing which cancers have increased CXCR4 expression can significantly impact clinical tumor staging and, subsequently, affect patient management and treatment decisions," said Andreas Buck, director of the department of nuclear medicine at University Hospital Würzburg in Würzburg, Germany.

"68Ga-PentixaFor PET is of particular interest because it offers improved lesion detection rates over other imaging modalities, such as MRI, CT, and even FDG PET."

In the study, researchers assessed 68Ga-PentixaFor uptake and image contrast to determine the most relevant clinical applications of CXCR4-directed imaging. Two study sites performed 68Ga-PentixaFor PET on 690 patients with 35 different types of cancer. Images were interpreted and statistical analyses performed.

Very high tracer uptake was found in patients with multiple myeloma, adrenocortical carcinoma, , adrenocortical adenoma, and . Comparable results were recorded for image contrast.

"These results suggest clinical scenarios in which 68Ga-PentixaFor PET may prove beneficial for directing CXCR4-targeted therapies," said Buck. "This is of particular importance for malignancies that lack a more suitable imaging modality. A pivotal phase III study is planned to continue this research in the second quarter of 2023."

More information: Andreas K. Buck et al, Imaging of C-X-C Motif Chemokine Receptor 4 Expression in 690 Patients with Solid or Hematologic Neoplasms using 68Ga-PentixaFor PET, Journal of Nuclear Medicine (2022). DOI: 10.2967/jnumed.121.263693

Journal information: Journal of Nuclear Medicine
Citation: Novel PET agent effectively detects multiple cancers, identifies patients for targeted therapies (2022, November 17) retrieved 17 June 2024 from
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.

Explore further

PET imaging tracer proves effective for diagnosing and managing rare CNS B-cell lymphoma


Feedback to editors